Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • U.S. Markets, Trends, and Opportunities in Patient Monitoring Products

    $4,750.00

    The intensity and high acuity of the critical care environment, combined with the shortage of experienced registered nurses, means that noninvasive and minimally invasive patient monitoring products will be in great demand during the forecast period covered by this report.

    November 1, 2013
    Find out more
  • RSV F Vaccine

    Read More

    RSV F vaccine is an intramuscular recombinant nanoparticle vaccine comprising a highly purified post-fusion form of the RSV F protein that can be administered with or without an alum adjuvant.

    October 5, 2018
    Find out more
  • Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

    $599.00

    The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

    October 30, 2020
    Find out more
  • Tasigna

    Read More

    Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division.

    December 7, 2017
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #1

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, and Lutetium 177Lu-PSMA-617.

    February 9, 2022
    Find out more
  • Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)​

    $1,318.00

    This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD)​ market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

    March 10, 2022
    Find out more
  • Hemlibra

    Read More

    Hemlibra is an anti-factor IXa/X bispecific antibody, developed by Roche as a new treatment option for hemophilia A patients.

    May 20, 2018
    Find out more
  • Sirukumab

    Read More

    Sirukumab (CNTO 136; Janssen/GlaxoSmithKline) is a human monoclonal antibody interleukin-6 receptor antagonist that is currently in Phase III development for rheumatoid arthritis.

    March 24, 2015
    Find out more
  • Acute Myeloid Leukemia (AML) KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include ASTX727, guadecitabine, idasanutlin, Iomab-B, oral azacitidine, pevonedistat, and Zeltherva.

    April 1, 2020
    Find out more
  • Key Potential Drug Launches in 2021

    $2,995.00

    As a supplement to our well-known quarterly Outlook report, Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2021.

    1.

    July 24, 2020
    Find out more
  • Activase

    Activase

    Read More

    Activase (alteplase; Roche/Boehringer Ingelheim/Kyowa Hakko Kirin) is a recombinant tissue plasminogen activator, and is a manufactured version of the tissue plasminogen activating proteins found naturally in endothelial cells.

    July 2, 2018
    Find out more
  • Alpelisib

    Read More

    Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.

    February 5, 2016
    Find out more
  • US Regulatory Issues

    $2,995.00

    Key regulatory developments include the new Prescription Drug User Fee Act (PDUFA-V), which aims to improve interaction between the FDA and drug developers.

    November 2, 2016
    Find out more
  • Vaccines Market Access in Emerging Markets

    $3,000.00

    Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

    August 29, 2019
    Find out more
  • Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention

    Read More

    Respiratory syncytial virus (RSV), a member of the Paramyxoviridae family, is an enveloped, non-segmented, single-stranded, negativesense RNA virus. It is a common respiratory virus that is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children.

    March 25, 2022
    Find out more
  • NOACs Pricing, Reimbursement, and Access

    $2,995.00

    A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers.

    May 10, 2017
    Find out more
  • Invanz

    Read More

    Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…

    June 19, 2015
    Find out more
  • lyrica report

    Lynparza

    Read More

    Lynparza (olaparib; AstraZeneca) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor. The PARP enzyme plays a central role in a number of cellular processes involved in cellular homeostasis.

    February 26, 2020
    Find out more
  • Aricept

    Read More

    Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
    Alzheimer’s disease for more than a decade.

    September 2, 2016
    Find out more
  • Psoriatic Arthritis: Market Access Pricing & Reimbursement

    $2,995.00

    Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market.

    October 17, 2016
    Find out more
  • Interventional Cardiology: Atherectomy and Thromboembolectomy

    $4,750.00

    The global market for atherectomy and thromboembolectomy products is anticipated to see moderate, single-digit growth throughout the forecast period covered by this analysis (2016-22). Growth in unit sales is being driven by the increasing prevalence of cardiovascular disease, which is the leading cause of death globally, responsible for over 17 million deaths annually.

    April 5, 2018
    Find out more
  • Apalutamide

    Read More

    Apalutamide (Johnson & Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently inhibits its nuclear import, as well as its ability to bind to DNA. Apalutamide has a similar mechanism of action to Xtandi (enzalutamide; Pfizer/Astellas).

    January 18, 2018
    Find out more
  • Disease Analysis: Multiple Myeloma

    Read More

    Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.

    May 25, 2022
    Find out more
  • GS-5745

    Read More

    GS-5745 (Gilead) is a humanized monoclonal antibody designed to selectively target the matrix metalloproteinase-9 (MMP9) enzyme. MMP9 plays a key role in the regulation of processes.

    July 21, 2016
    Find out more
  • Market Spotlight: Lysosomal Storage Disorders

    $1,318.00

    This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.

    April 28, 2022
    Find out more
  • fostemsavir

    Read More

    Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV to prevent viral attachment to the host CD4+ T cells, which is necessary for entry into host cells.

    June 28, 2019
    Find out more
  • Briviacti

    Read More

    Briviact (brivaracetam; UCB) is a follow-on product to Keppra (levetiracetam; UCB/Otsuka), acting as an anticonvulsant by binding to the synaptic vesicle glycoprotein 2A (SV2A), directly causing…

    June 7, 2016
    Find out more
  • bb2121

    Read More

    Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.

    August 9, 2018
    Find out more
  • Onfi

    Read More

    Onfi is a 1,5-benzodiazepine that acts by potentiating gamma-aminobutyric acid (GABA)ergic transmission through binding at the GABA[A] receptor.

    May 23, 2017
    Find out more
  • Fluad QIV

    Read More

    Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • Firsocostat

    Read More

    Firsocostat (Gilead) is an acetyl-CoA carboxylase (ACC) allosteric inhibitor which binds to the biotin carboxylase domain of ACC with high potency and selectivity. Firsocostat inhibits both isoforms (ACC1 and ACC2) of ACC, which results in the reduction of the production of malonyl-CoA carboxylase, therefore reducing a key substrate for fatty acid synthesis. This also reduces the inhibitory effect of malonyl-CoA on the carnitine palmitoyltransferase 1 (CPT-1), which is the rate-limiting step in β-oxidation and leads to an increase in the breakdown of free fatty acids.

    July 22, 2019
    Find out more
  • lovaza report

    Lovaza

    Read More

    Lovaza (omega-3-acid ethyl esters; GlaxoSmithKline/AbbVie/Takeda) was the first omega-3 fatty acid formulation to receive approval from the US Food and Drug Administration for the treatment of severe hypertriglyceridemia.

    June 22, 2018
    Find out more
  • Ocaliva

    Read More

    Ocaliva (obeticholic acid; Intercept Pharmaceuticals) is a selective farnesoid X receptor (FXR) agonist. FXR is a nuclear bile acid receptor involved in the regulation of bile acids, lipids, and possibly glucose. Ocaliva is a derivative of chenodeoxycholic acid, the endogenous FXR agonist found naturally in human bile acid. By activating FXR, Ocaliva improves insulin sensitivity and inhibits lipogenesis, which reduces fat buildup in the liver and results in decreased inflammation. Ocaliva has also been linked to weight loss. Ocaliva is currently approved in the US and EU for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

    July 22, 2019
    Find out more
  • Xalkori

    Read More

    Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor

    August 30, 2018
    Find out more
  • prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

    Prostate Cancer: Market Access Pricing & Reimbursement

    $2,995.00

    The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

    June 1, 2018
    Find out more
  • Nuplazid

    Read More

    Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors.

    March 19, 2018
    Find out more
  • Live-attenuated RSV vaccines

    Read More

    In collaboration with the National Institute of Allergy and Infectious Diseases, AstraZeneca is developing a portfolio of three live-attenuated vaccines for the prevention of serious lower respiratory tract infections.

    October 5, 2018
    Find out more
  • Market Spotlight: Small-Cell Lung Cancer (SCLC)

    $1,318.00

    This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    May 19, 2022
    Find out more
  • Zontivity

    Read More

    Zontivity (vorapaxar; Merck & Co) gained US and EU approval for the reduction of thromboembolic

    events in secondary-prevention patients with a history of myocardial infarction (MI).

    April 14, 2016
    Find out more
  • Disruptive Innovation and the Pharmaceutical Contract Services Sector

    $5,000.00

    With the pharmaceutical sector currently in the middle of such a transformative cycle, are drug developers or the firms providing them with outsourced research or manufacturing services going to find themselves similarly left behind?

    November 3, 2016
    Find out more
  • Biopharma Quarterly Dealmaking Statistics, Q3 2016

    Biopharma Quarterly Dealmaking Statistics, Q3 2016

    $499.00

    A look at biopharma financing, M&A and alliance activity July–September 2016, based on data from Strategic Transactions.

    November 18, 2016
    Find out more
  • Pulse Oximetry Devices Market

    $3,000.00

    This report provides an overview of pulse oximetry, and profiles selected leading products and technologies. The report also provides a market and competitive analysis of the global pulse oximetry devices market, including five-year market forecast and share by supplier.

    December 22, 2017
    Find out more
  • Pulmonary hypertension

    Disease Analysis: Pulmonary Hypertension

    Read More

    Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.

    May 20, 2022
    Find out more
  • Gantenerumab

    Read More

    Gantenerumab (Roche/MorphoSys) is a fully humanized centrally and N-acting monoclonal antibody that primarily targets fibrillar amyloid-beta.

    September 2, 2016
    Find out more
  • Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    $599.00

    An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.

    March 17, 2022
    Find out more
Page 1 of 29
Page 1 of 29123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top